{"brief_title": "A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma", "brief_summary": "Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.", "detailed_description": "In addition to the key secondary outcome parameters the following exploratory parameters were evaluated in subpopulations: - Pharmacokinetics (PK) profile of Sorafenib - Plasma and tissue tumor biomarkers", "condition": ["Carcinoma, Hepatocellular"], "intervention_type": ["Drug"], "intervention_name": ["Sorafenib (Nexavar, BAY43-9006)"], "description": ["Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)"], "arm_group_label": ["Sorafenib 400 mg b.i.d."], "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed primary hepatocellular carcinoma (HCC) - Inoperable disease (T2-T4, any N, M0 or M1) or refused surgery - Measurable disease - At least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography (CT) scan or magnetic resonance imaging (MRI) - Presence of at least 1 of the following: - Alpha-fetoprotein greater than the upper limit of normal (ULN) - Hepatitis C antibody positive - Hepatitis B surface antigen positive - Child's Pugh class A or B - Candidate for systemic therapy Exclusion Criteria: - Fibrolamellar disease mixed histology - Metastatic brain or meningeal tumors", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Hepatocellular carcinoma (HCC)", "mesh_term": ["Carcinoma", "Carcinoma, Hepatocellular", "Sorafenib", "Niacinamide"], "id": "NCT00044512"}